A First-In-Class Tri-complex KRAS-G13C(ON) Inhibitor Validates Therapeutic Targeting of KRAS-G13C and Drives Tumor Regressions in Preclinical Models

Christopher J. Schulze, Jim Cregg, Kyle J. Seamon, Yu Chi Yang, Zhican Wang, Lindsay S. Garrenton, Alun Bermingham, John E. Knox, Aidan Tomlinson, Kang-Jye Chou, Shaoling Li, David P. Wildes, Mallika Singh, Elena S. Koltun, Adrian L. Gill, Robert J. Nichols, Jacqueline A. M. Smith.